Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07670884 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jul 2027 → Oct 31, 2027
See other at-risk trials from Fujian Shengdi Pharmaceutical Co., Ltd.

Record History

  1. Start date: Jul 17, 2026 to Jul 24, 2026v3
  2. Recruitment opened Enrollment increased: 425 → 675 participants · Primary completion pushed from Jul 2027 to Oct 31, 2027 · Completion pushed from Aug 2027 to Nov 30, 2027 · 2 morev2 Show 5 more changesShow less
    • Enrollment increased: 425 → 675 participants
    • Primary completion pushed from Jul 2027 to Oct 31, 2027
    • Completion pushed from Aug 2027 to Nov 30, 2027
    • Start date changed from estimate of Jul 2026 to Jul 17, 2026
    • Site details revised at 2 of 2 sites
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
Trial Details
NCT Number NCT07670884
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Chronic Management of Body Weight
Enrollment 675 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov